President Trump’s chief cost-cutter cheered an effort to persuade federal workers to quit — in a fashion that closely ...

Robert F. Kennedy Jr., if confirmed as HHS secretary, could help food-as-medicine startups expand with wider government health plan coverage.

As with many other companies Eli Lilly and Company (NYSE:LLY) makes use of debt. But the more important question is: how much risk is that debt creating? Debt and other liabilities become risky ...

AI decentralized autonomous organization (DAO) ai16z has changed its name to ElizaOS following concerns from tech venture capital firm Andreessen Horowitz (a16z) over brand confusion. The rebrand ...

Eli Lilly (LLY) closed the latest trading day at $804.99, indicating a -0.39% change from the previous session's end. The stock trailed the S&P 500, which registered a daily gain of 0.92%.

Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The company had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion.

LLY stock opened at $803.01 on Tuesday. The company has a market capitalization of $762.31 billion, a P/E ratio of 86.81, a PEG ratio of 1.59 and a beta of 0.41. Eli Lilly and Company has a twelve ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

I think Eli Lilly and Company's stock correction may be ending as demand for key drugs Zepbound and Mounjaro remains strong, despite recent sales guidance cuts. The company's high valuation ...

Leerink notes Eli Lilly (LLY) terminated its volenrelaxin CKD due to failure of a “related heart failure study,” which has caused significant concern about the likelihood of success of ...